{"blog": [], "keywords": [{"value": "Corporate Taxes", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Treasury Department", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Tax Shelters", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "ALLERGAN INC", "name": "organizations", "rank": "5", "is_major": "N"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Federal Taxes (US)", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "Obama, Barack", "name": "persons", "rank": "8", "is_major": "N"}, {"value": "Internal Revenue Service", "name": "organizations", "rank": "9", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/08/opinion/free-pfizer-why-inversions-are-good-for-the-us.html", "document_type": "article", "byline": {"person": [{"lastname": "FURCHTGOTT-ROTH", "firstname": "Diana", "role": "reported", "organization": "", "rank": 1}], "original": "By DIANA FURCHTGOTT-ROTH"}, "type_of_material": "Op-Ed", "multimedia": [{"url": "images/2016/04/07/opinion/08furchtgott/08furchtgott-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/opinion/08furchtgott/08furchtgott-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/07/opinion/08furchtgott/08furchtgott-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/opinion/08furchtgott/08furchtgott-articleLarge.jpg", "xlargeheight": "454", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 454}, {"url": "images/2016/04/07/opinion/08furchtgott/08furchtgott-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/opinion/08furchtgott/08furchtgott-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Opinion", "word_count": "842", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The new Obama administration rules will ultimately discourage companies from investing in the U.S.", "pub_date": "2016-04-08T00:00:00Z", "news_desk": "OpEd", "headline": {"kicker": "Op-Ed Contributor", "print_headline": "Free Pfizer! Why Inversions Help", "main": "Free Pfizer! Why Inversions Are Good for the U.S.", "content_kicker": "Op-Ed Contributor"}, "print_page": "25", "snippet": "The new Obama administration rules will ultimately discourage companies from investing in the U.S.", "_id": "5706ce4138f0d80c57594f1e", "slideshow_credits": null, "abstract": "Op-Ed article by economist Diana Furchgott-Roth argues new Treasury Dept regulations aimed at limiting corporate inversions are unlikely to benefit United Sates; holds country's high statutory corporate taxes unfairly punish American-based multinationals; suggests solution is lower taxes, not burdensome new rules."}